ASCO Guidelines
By American Society of Clinical Oncology (ASCO)
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 21
Reviews: 0
Episodes: 156
Description
ASCO Guidelines features key recommendations from the latest evidence-based clinical practice guidance from ASCO that you can access on the go.
| Episode | Date |
|---|---|
|
Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASCO Guideline
|
May 01, 2024 |
|
Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations
|
Apr 29, 2024 |
|
Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline Update
|
Mar 19, 2024 |
|
Vaccination of Adults with Cancer Guideline
|
Mar 18, 2024 |
|
Cannabis and Cannabinoids in Adults with Cancer Guideline
|
Mar 13, 2024 |
|
Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update
|
Mar 13, 2024 |
|
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.3 Part 2
|
Feb 28, 2024 |
|
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2023.3 Part 1
|
Feb 28, 2024 |
|
Systemic Treatment of Patients with Metastatic Breast Cancer Resource-Stratified Guideline
|
Jan 10, 2024 |
|
Germline Testing in Patients with Breast Cancer: ASCO-SSO Guideline
|
Jan 04, 2024 |
|
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation Update
|
Nov 06, 2023 |
|
Systemic Therapy for SCLC: ASCO-OH (CCO) Guideline
|
Oct 11, 2023 |
|
Management of Metastatic Renal Clear Cell Cancer Rapid Recommendation Update
|
Oct 10, 2023 |
|
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated GEP-NETs Guideline
|
Sep 29, 2023 |
|
Systemic Therapy for Melanoma Guideline Update
|
Sep 06, 2023 |
|
Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline
|
Aug 15, 2023 |
|
Management of Stage III NSCLC Rapid Recommendation Update
|
Jul 20, 2023 |
|
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy Guideline Update
|
Jul 17, 2023 |
|
Cancer Cachexia Rapid Recommendation Update
|
Jul 12, 2023 |
|
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.2
|
Jul 11, 2023 |
|
HER2 Testing in Breast Cancer: ASCO-CAP Guideline Update
|
Jun 07, 2023 |
|
Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Rapid Recommendation Update
|
May 17, 2023 |
|
VTE Prophylaxis and Treatment in Patients with Cancer Guideline Update
|
Apr 19, 2023 |
|
Management of Anxiety and Depression in Adult Survivors of Cancer Guideline Update
|
Apr 19, 2023 |
|
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2023.1 Part 2
|
Apr 06, 2023 |
|
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2023.1 Part 1
|
Apr 06, 2023 |
|
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer Guideline Update
|
Apr 03, 2023 |
|
Penile Cancer: EAU-ASCO Guideline
|
Mar 10, 2023 |
|
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update
|
Jan 20, 2023 |
|
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline
|
Jan 06, 2023 |
|
Targeted Therapy and Immunotherapy for Gastroesophageal Cancer Guideline
|
Jan 05, 2023 |
|
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2022.2 Part 2
|
Dec 19, 2022 |
|
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2022.2 Part 1
|
Dec 19, 2022 |
|
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers Guideline
|
Dec 15, 2022 |
|
Use of Opioids for Adults with Pain from Cancer or Cancer Treatment Guideline
|
Dec 05, 2022 |
|
Treatment of Metastatic Colorectal Cancer Guideline
|
Oct 17, 2022 |
|
PARP Inhibitors in the Management of Ovarian Cancer Rapid Recommendation Update
|
Oct 03, 2022 |
|
Secondary Prevention of Cervical Cancer Resource-Stratified Guideline Update
|
Sep 26, 2022 |
|
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation Update
|
Sep 21, 2022 |
|
Integrative Medicine for Pain Management in Oncology: SIO-ASCO Guideline
|
Sep 19, 2022 |
|
Chemotherapy and Targeted Therapy for HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update
|
Aug 04, 2022 |
|
Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations: ASCO Living Guideline (Part 1)
|
Jul 11, 2022 |
|
Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline (Part 2)
|
Jul 11, 2022 |
|
Biomarkers for Systemic Therapy in Metastatic Breast Cancer Guideline Update
|
Jun 27, 2022 |
|
Management of Metastatic Clear Cell Renal Cell Carcinoma Guideline
|
Jun 21, 2022 |
|
Systemic Therapy for Melanoma Rapid Recommendation Update
|
Jun 03, 2022 |
|
Systemic Therapy for Advanced HER2-Positive Breast Cancer Guideline Update
|
May 31, 2022 |
|
Management of Advanced HER2-Positive Breast Cancer and Brain Metastases Guideline Update
|
May 31, 2022 |
|
Exercise, Diet, and Weight Management During Cancer Treatment Guideline
|
May 16, 2022 |
|
Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline
|
May 13, 2022 |
|
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer Guideline Update
|
Apr 19, 2022 |
|
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Triple Negative Breast Cancer Rapid Recommendation Update
|
Apr 13, 2022 |
|
Management and Care of Patients with Invasive Cervical Cancer: Resource-Stratified Guideline Rapid Recommendation Update
|
Mar 07, 2022 |
|
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
|
Feb 24, 2022 |
|
Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer Provisional Clinical Opinion
|
Feb 17, 2022 |
|
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected NSCLC Guideline Rapid Recommendation Update
|
Feb 14, 2022 |
|
Management of Stage III NSCLC Guideline
|
Dec 22, 2021 |
|
Adjuvant Therapy for Stage II Colon Cancer Guideline Update
|
Dec 22, 2021 |
|
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
|
Dec 21, 2021 |
|
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
|
Dec 13, 2021 |
|
Abemaciclib with Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
|
Dec 10, 2021 |
|
Considerations for the Use of Steroids: Management of irAEs Guideline (Part 13)
|
Nov 16, 2021 |
|
Ocular Toxicities: Management of irAEs Guideline (Part 12)
|
Nov 15, 2021 |
|
Cardiovascular Toxicities: Management of irAEs Guideline (Part 11)
|
Nov 12, 2021 |
|
Hematologic Toxicities: Management of irAEs Guideline (Part 10)
|
Nov 11, 2021 |
|
Nervous System Toxicities: Management of irAEs Guideline (Part 9)
|
Nov 10, 2021 |
|
Renal Toxicities: Management of irAEs Guideline (Part 8)
|
Nov 09, 2021 |
|
Musculoskeletal Toxicities: Management of irAEs Guideline (Part 7)
|
Nov 08, 2021 |
|
Endocrine Toxicities: Management of irAEs Guideline (Part 6)
|
Nov 05, 2021 |
|
Lung Toxicities: Management of irAEs Guideline (Part 5)
|
Nov 04, 2021 |
|
Gastrointestinal Toxicities: Management of irAEs Guideline (Part 4)
|
Nov 03, 2021 |
|
Cutaneous Toxicities: Management of irAEs Guideline (Part 3)
|
Nov 02, 2021 |
|
CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)
|
Nov 01, 2021 |
|
ICPi Overview: Management of irAEs Guideline (Part 1)
|
Nov 01, 2021 |
|
Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update
|
Aug 18, 2021 |
|
Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
|
Aug 03, 2021 |
|
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Guideline Update
|
Jul 29, 2021 |
|
Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Guideline Update
|
Jul 29, 2021 |
|
Telehealth in Oncology: Standards and Practice Recommendations
|
Jul 28, 2021 |
|
Salivary Gland Hypofunction and/or Xerostomia Induced by Non-Surgical Cancer Therapies: ISOO/MASCC/ASCO Guideline
|
Jul 20, 2021 |
|
Management of the Axilla in Early-Stage Breast Cancer: OH (CCO) and ASCO Guideline
|
Jul 19, 2021 |
|
Oncology Medical Home: ASCO and COA Standards
|
Jul 13, 2021 |
|
Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer Resource Stratified Guideline
|
Jun 29, 2021 |
|
Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer Guideline Update
|
May 03, 2021 |
|
Management of Salivary Gland Malignancy Guideline
|
Apr 26, 2021 |
|
Management of Dyspnea in Advanced Cancer Guideline
|
Feb 22, 2021 |
|
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Guideline Update
|
Feb 16, 2021 |
|
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline
|
Jan 28, 2021 |
|
Radiation Therapy for Small Cell Lung Cancer Guideline Endorsement
|
Jan 27, 2021 |
|
Initial Management of Non-Castrate Advanced, Recurrent, or Metastatic Prostate Cancer Guideline Update
|
Jan 26, 2021 |
|
PREVIEW: ASCO in Action CEO & CMO Interview
|
Jan 19, 2021 |
|
Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage II to IVA Nasopharyngeal Carcinoma: CSCO-ASCO Guideline
|
Jan 06, 2021 |
|
Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline
|
Nov 16, 2020 |
|
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Update
|
Oct 20, 2020 |
|
Treatment of Metastatic Carcinoma and Myeloma of the Femur: Joint MSTS/ASTRO/ASCO Guideline
|
Oct 01, 2020 |
|
PARP Inhibitors in the Management of Ovarian Cancer Guideline
|
Aug 13, 2020 |
|
Metastatic Pancreatic Cancer Guideline Update
|
Aug 05, 2020 |
|
Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy Provisional Clinical Opinion Update
|
Jul 27, 2020 |
|
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers Guideline Update
|
Jul 14, 2020 |
|
Antiemetics Guideline Update
|
Jul 13, 2020 |
|
Treatment of Locally Advanced Esophageal Carcinoma Guideline
|
Jun 22, 2020 |
|
Management of Cancer Cachexia Guideline
|
May 20, 2020 |
|
Lung Cancer Surveillance After Definitive Curative-Intent Therapy Guideline
|
May 07, 2020 |
|
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Guideline
|
Apr 23, 2020 |
|
Management of Hereditary Breast Cancer Guideline
|
Apr 03, 2020 |
|
Systemic Therapy for Melanoma Guideline
|
Mar 31, 2020 |
|
Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline
|
Mar 09, 2020 |
|
Management of Male Breast Cancer Guideline
|
Feb 14, 2020 |
|
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations Guideline
|
Jan 28, 2020 |
|
Bone Health and Bone-Targeted Therapies for Prostate Cancer Guideline Endorsement
|
Jan 28, 2020 |
|
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer Guideline
|
Jan 27, 2020 |
|
Optimum Imaging Strategies for Advanced Prostate Cancer Guideline
|
Jan 15, 2020 |
|
Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update
|
Jan 13, 2020 |
|
Molecular Biomarkers in Localized Prostate Cancer Guideline
|
Dec 12, 2019 |
|
Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards
|
Dec 09, 2019 |
|
Management of Osteoporosis in Survivors of Adult Cancers with Nonmetastatic Disease Guideline
|
Sep 18, 2019 |
|
Use of Endocrine Therapy for Breast Cancer Risk Reduction Guideline
|
Sep 03, 2019 |
|
Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer Guideline Update
|
Aug 05, 2019 |
|
Medication-Related Osteonecrosis of the Jaw Guideline
|
Jul 22, 2019 |
|
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Update
|
Jun 17, 2019 |
|
Potentially Curable Pancreatic Adenocarcinoma Guideline Update
|
Jun 10, 2019 |
|
Use of Biomarkers to Guide Decisions on Adjuvant Therapy for Early-Stage Invasive Breast Cancer Guideline Update
|
May 31, 2019 |
|
Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer PCO
|
Apr 25, 2019 |
|
Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer Guideline
|
Apr 15, 2019 |
|
Management of Cancer-associated Anemia with Erythropoiesis-Stimulating Agents Guideline
|
Apr 10, 2019 |
|
Treatment of Multiple Myeloma Guideline
|
Apr 01, 2019 |
|
Anticonvulsant Prophylaxis and Steroid Use in Adults with Metastatic Brain Tumors Endorsement
|
Mar 18, 2019 |
|
Adjuvant Therapy for Resected Biliary Tract Cancer Guideline
|
Mar 11, 2019 |
|
Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Guideline
|
Feb 27, 2019 |
|
Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline
|
Feb 25, 2019 |
|
Early Detection for Colorectal Cancer Resource-Stratified Guideline
|
Feb 25, 2019 |
|
Safe Handling of Hazardous Drugs: ASCO Standards
|
Jan 08, 2019 |
|
Initial Diagnostic Workup of Acute Leukemia Guideline
|
Dec 03, 2018 |
|
Evaluating Susceptibility to Pancreatic Cancer PCO
|
Nov 20, 2018 |
|
Adjuvant Endocrine Therapy for Women with Hormone Receptor Positive Breast Cancer Guideline
|
Nov 19, 2018 |
|
Hypofractionated Radiation Therapy for Localized Prostate Cancer Guideline
|
Oct 11, 2018 |
|
Human Papillomavirus Testing in Head and Neck Carcinomas Endorsement Guideline
|
Sep 06, 2018 |
|
Clinically Localized Prostate Cancer Endorsement Guideline
|
Sep 05, 2018 |
|
Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression Guideline
|
Sep 04, 2018 |
|
Disease Management for Patients With Advanced HER2 Positive Breast Cancer and Brain Metastases Guideline
|
Jun 25, 2018 |
|
Systemic Therapy for Patients with Advanced HER2 Positive Breast Cancer Guideline
|
Jun 25, 2018 |
|
Integrative Therapies During and After Breast Cancer Treatment Guideline
|
Jun 11, 2018 |
|
Treatment of Malignant Pleural Mesothelioma Guideline
|
Jun 05, 2018 |
|
HER2 Testing in Breast Cancer Guideline
|
May 30, 2018 |
|
Metastatic Pancreatic Cancer Guideline
|
May 23, 2018 |
|
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline
|
May 22, 2018 |
|
Practical Assessment and Management of Vulnerabilities in Older Patients Guideline
|
May 21, 2018 |
|
ASCO Clinical Practice Guidelines Committee Leadership
|
May 14, 2018 |
|
Palliative Care in the Global Setting Guideline
|
May 08, 2018 |
|
Antiemetics Guideline
|
May 04, 2018 |
|
Patient-Clinician Communication Consensus Guideline
|
Apr 27, 2018 |
|
Integration of Palliative Care into Oncology Guideline
|
Apr 18, 2018 |
|
Fertility Preservation in Patients with Cancer Guideline
|
Apr 05, 2018 |
|
Optimizing Anticancer Therapy in Prostate Cancer Guideline
|
Apr 02, 2018 |
|
Outpatient Management of Fever and Neutropenia Guideline
|
Feb 20, 2018 |
|
Management of Immune-Related Adverse Events Guideline
|
Feb 14, 2018 |